These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19912599)

  • 1. The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model.
    Knight C; Howard P; Baker CL; Marton JP
    Value Health; 2010; 13(2):209-14. PubMed ID: 19912599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of an extended course (12+12 weeks) of varenicline plus brief counselling compared with other reimbursed smoking cessation interventions in Belgium, from a public payer perspective.
    Knight C; Marbaix S; Annemans L; Prignot J; Bowrin K
    Acta Clin Belg; 2012; 67(6):416-22. PubMed ID: 23340147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
    Linden K; Jormanainen V; Linna M; Sintonen H; Wilson K; Kotomäki T
    Curr Med Res Opin; 2010 Mar; 26(3):549-60. PubMed ID: 20050814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-term cost-effectiveness of varenicline (12-week standard course and 12 + 12-week extended course) vs. other smoking cessation strategies in Canada.
    von Wartburg M; Raymond V; Paradis PE
    Int J Clin Pract; 2014 May; 68(5):639-46. PubMed ID: 24472120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.
    Annemans L; Nackaerts K; Bartsch P; Prignot J; Marbaix S
    Clin Drug Investig; 2009; 29(10):655-65. PubMed ID: 19715382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
    Lutz MA; Lovato P; Cuesta G
    Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varenicline in the management of smoking cessation: a single technology appraisal.
    Hind D; Tappenden P; Peters J; Kenjegalieva K
    Health Technol Assess; 2009 Sep; 13 Suppl 2():9-13. PubMed ID: 19804684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.
    Bolin K; Mörk AC; Willers S; Lindgren B
    Respir Med; 2008 May; 102(5):699-710. PubMed ID: 18289839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.
    Keating GM; Lyseng-Williamson KA
    Pharmacoeconomics; 2010; 28(3):231-54. PubMed ID: 20108995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease.
    Lock K; Wilson K; Murphy D; Riesco JA
    Expert Opin Pharmacother; 2011 Dec; 12(17):2613-26. PubMed ID: 22017336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation.
    Mahmoudi M; Coleman CI; Sobieraj DM
    Int J Clin Pract; 2012 Feb; 66(2):171-82. PubMed ID: 22257042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Varenicline: a first-line treatment option for smoking cessation.
    Garrison GD; Dugan SE
    Clin Ther; 2009 Mar; 31(3):463-91. PubMed ID: 19393839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers.
    Howard P; Knight C; Boler A; Baker C
    Pharmacoeconomics; 2008; 26(6):497-511. PubMed ID: 18489200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
    Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
    Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
    Hoogendoorn M; Welsing P; Rutten-van Mölken MP
    Curr Med Res Opin; 2008 Jan; 24(1):51-61. PubMed ID: 18021492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoking-cessation therapy using varenicline: the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence.
    Bolin K; Mörk AC; Wilson K
    J Eval Clin Pract; 2009 Jun; 15(3):478-85. PubMed ID: 19536915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
    Lutz MA; Lovato P; Cuesta G
    Hosp Pract (1995); 2012 Feb; 40(1):35-43. PubMed ID: 22406881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.
    Leaviss J; Sullivan W; Ren S; Everson-Hock E; Stevenson M; Stevens JW; Strong M; Cantrell A
    Health Technol Assess; 2014 May; 18(33):1-120. PubMed ID: 24831822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of copayment on initiation of smoking cessation pharmacotherapy: an analysis of varenicline reversed claims.
    Zeng F; Chen CI; Mastey V; Zou KH; Harnett J; Patel BV
    Clin Ther; 2011 Feb; 33(2):225-34. PubMed ID: 21497706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of cost-utility of varenicline compared with existing smoking cessation therapies in South Korea.
    Bae JY; Kim CH; Lee EK
    Value Health; 2009; 12 Suppl 3():S70-3. PubMed ID: 20586986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.